The Reduction of Serum B‐Lymphocyte Activating Factor levels following Quinacrine Add‐On Therapy in Systemic Lupus Erythematosus

Elias Toubi(Bnai Zion Medical Center), Y Shoenfeld(Tel Aviv University), Itzhak Rosner(Bnai Zion Medical Center), D. Paran(Tel Aviv Sourasky Medical Center), Michael Rozenbaum(Bnai Zion Medical Center), Aharon Kessel(Technion – Israel Institute of Technology)
Scandinavian Journal of Immunology
March 8, 2006
10.1111/j.1365-3083.2006.01737.x
Cited by 41

Related Papers

International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
|Journal of Thrombosis and Haemostasis|2006|7.1k
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.4k
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
|Allergy|2021|1.2k
The <scp>EAACI</scp>/<scp>GA</scp><sup>2</sup><scp>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
|Allergy|2014|1.2k
The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
|Dermatology Review|2015|428